Table 1.

Characteristics of all patients included in the study

	Total	Cancer	Noncancer	P	N-CSPCaa	P	CSPCab	P
Number	197	47	150		17		30
Age (year)	66.45±8.04	68.51±7.89	65.81±8.00	0.044	67.12±7.52	0.048	69.30±8.10	0.037
PV (cc)	44.20±18.44	35.82±19.22	46.83±17.44	0.001	37.68±23.99	0.003	34.76±16.29	0.001
t-PSA (ng ml−1)	7.05±1.64	7.38±1.65	6.93±1.62	0.111	7.21±1.81	0.556	7.48±1.58	0.097
f-PSA (ng ml−1)	1.35±1.08	1.20±0.76	1.39±1.16	0.191	1.37±1.06	0.919	1.15±0.52	0.056
F/T PSA	0.18±0.07	0.16±0.07	0.19±0.07	0.017	0.17±0.08	0.024	0.15±0.07	0.016
PSAD (ng ml−1 cc−1)	0.19±0.09	0.25±0.17	0.17±0.07	<0.001	0.23±0.10	0.002	0.26±1.30	0.001

^aN-CSPCa vs noncancer; ^bCSPCa vs noncancer. PV: prostate volume (cc); t-PSA: total prostate-specific antigen (ng ml⁻¹); f-PSA: free prostate-specific antigen (ng ml⁻¹); F/T PSA: free/total PSA ratio; PSAD: PSA density (ng ml⁻¹ cc⁻¹); N-CSPCa: nonclinically significant prostate cancers; CSPCa: clinically significant prostate cancers